EP2501710A2 - Process for preparing (11beta, 16alpha)-9-fluoro-11-hydroxy-16,17-[1-methyl-ethylidenebis(oxy)]-21-[1-oxo-[4-(nitrooxymethyl)benzoxy]]pregna-1,4-dien-3,20-dione - Google Patents

Process for preparing (11beta, 16alpha)-9-fluoro-11-hydroxy-16,17-[1-methyl-ethylidenebis(oxy)]-21-[1-oxo-[4-(nitrooxymethyl)benzoxy]]pregna-1,4-dien-3,20-dione

Info

Publication number
EP2501710A2
EP2501710A2 EP10776364A EP10776364A EP2501710A2 EP 2501710 A2 EP2501710 A2 EP 2501710A2 EP 10776364 A EP10776364 A EP 10776364A EP 10776364 A EP10776364 A EP 10776364A EP 2501710 A2 EP2501710 A2 EP 2501710A2
Authority
EP
European Patent Office
Prior art keywords
solvent
process according
acid
chosen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10776364A
Other languages
German (de)
French (fr)
Inventor
Luis Anglada
Albert Palomer
Luis Sobral
Carlos ÁLVAREZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferrer Internacional SA
Nicox SA
Original Assignee
Ferrer Internacional SA
Nicox SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43896867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2501710(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrer Internacional SA, Nicox SA filed Critical Ferrer Internacional SA
Publication of EP2501710A2 publication Critical patent/EP2501710A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • This invention relates to a new process for the preparation of the compound (1 1 ⁇ , 16a)-9-fluoro-1 1 -hydroxy-16,17-[1 -methyl- ethyl idenebis(oxy)]-21 -[1 -oxo-[4-(nitrooxymethyl)benzoxy]]pregna-1 ,4-dien- 3,20-dione, used as a topic anti-inflammatory drug.
  • Compound (1 1 ⁇ , 16a)-9-fluoro-1 1 -hydroxy-16,17-[1 -methyl- ethylidenebis(oxy)]-21 -[1 -oxo-[4-(nitrooxymethyl)benzoxy]]pregna-1 ,4-dien- 3,20-dione with formula (I) is a corticosteroid previously described in application WO2007025632 (Example 1 ). This compound is especially useful in the treatment of certain inflammatory diseases such as corticosteroid- sensitive dermatosis, atopic dermatitis, contact dermatitis, psoriasis and seborrhoeic dermatitis.
  • Said compound is applied topically, preferably using creams, ointments, lotions and gels and similar formulations.
  • the compound of formula (I) is obtained in example 1 of application WO2007025632 by the reaction of triamcinolone acetonide (II) with 4- (nitrooxymethyl)benzoic acid (III) in the presence of 1 -ethyl-3-(3- dimethylaminopropyl)carbodiimide (IV) and 4-dimethylaminopyridine (V) according to Diagram 1 .
  • the invention provides a new industrial process for preparing (1 1 ⁇ , 16a)-9-fluoro-1 1 -hydroxy-16,17-[1 -methyl-ethyl idenebis(oxy)]- 21 -[1 -oxo-[4-(nitrooxymethyl)benzoxy]]pregna-1 ,4-dien-3,20-dione (I) with a good yield, starting from cost effective products and providing an end product with suitable purity and particle size.
  • the solvent of step (i) is chosen from the group consisting of halogenated hydrocarbons such as dichloromethane, amides such as dimethylformamide and dimethylacetamide, cyclic ethers such as tetrahydrofurane, ketones such as acetone and methyl isobutyl ketone, esters such as ethyl acetate and isopropyl acetate, nitriles such as acetonitrile, sulphoxides such as dimethyl sulphoxide and similar solvents and mixtures thereof.
  • the solvent is preferably dichloromethane.
  • the acidification is performed with an acid chosen from the group consisting of mineral acids such as hydrochloric acid, sulphuric acid, phosphoric acid and hydrobromic acid, carboxylic acids such as acetic acid, trifluoroacetic acid and formic acid, sulphonic acids such as methane sulphonic acid, trifluoromethane sulphonic acid and p-toluene sulphonic acid and other similar acids and mixtures thereof.
  • the acid is preferably hydrochloric acid.
  • the neutralisation is performed with a base chosen from the group consisting of alkaline bicarbonates such as sodium bicarbonate and potassium bicarbonate and alkaline carbonate such as sodium carbonate and potassium carbonate.
  • the base is preferably sodium bicarbonate.
  • the anti-solvent of step (i) is chosen from the group consisting of Ci-C 4 alkanols such as ethanol, methanol and isopropanol, aromatic hydrocarbons such as toluene and xylenes, as well as water and other similar anti-solvents and mixtures thereof.
  • the anti-solvent is preferably ethanol.
  • the solvent of step (ii) is chosen from the group consisting of halogenated hydrocarbons such as dichloromethane, amides such as dimethylformamide and dimethylacetamide, cyclic ethers such as tetrahydrofurane, ketones such as acetone and methyl isobutyl ketone, esters such as ethyl acetate and isopropyl acetate, nitriles such as acetonitrile, sulphoxides such as dimethyl sulphoxide and similar solvents and mixtures thereof.
  • the solvent is preferably dichloromethane.
  • the anti-solvent of step (ii) is chosen from the group consisting of Ci-C 4 alkanols such as ethanol, methanol and isopropanol, aromatic hydrocarbons such as toluene and xylenes, as well as water and other similar anti-solvents and mixtures thereof.
  • the anti-solvent is preferably ethanol.
  • the solvent of step (iii) is chosen from the group consisting of esters such as ethyl acetate and isopropyl acetate, amides such as dimethylformamide and dimethylacetamide, cyclic ethers such as tetrahydrofurane, ketones such as acetone and methyl isobutyl ketone, nitriles such as acetonitrile, halogenated hydrocarbons such as dichloromethane and sulphoxides such as dimethyl sulphoxide and similar solvents and mixtures thereof.
  • the solvent is preferably ethyl acetate.
  • the anti-solvent of step (iii) is chosen from a group consisting of C6-C9 aliphatic hydrocarbons such as heptane, aliphatic ethers such as isopropyl ether and ethyl ether, the group consisting of Ci-C 4 alkanols such as ethanol, methanol and isopropanol, and similar anti- solvents and mixtures thereof.
  • the anti-solvent is preferably heptane. Examples Example 1
  • the dichloromethane extracts were placed together and 203 I of 0.5 N HCI were added.
  • 203 I of 0.5 N HCI were added to the organic phase, followed by 129 I of 0.25 N NaHCO3. It was washed with water until the pH of the aqueous phase was similar to that of the water added.
  • the wet solid was dried under vacuum.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

This invention relates to a new process for preparing (11 β, 16α)-9-fluoro-11 - hydroxy-16,17-[1 -methyl -ethyl idenebis(oxy)]-21 -[1 -oxo-[4- (nitrooxymethyl)benzoxy]]pregna-1,4-dien-3,20-dione, comprising the steps of (i) reaction of triamcinolone acetonide with 4-(nitrooxymethyl)benzoic, 4- dimethylaminopyridine and N-N'-diisopropylcarbodiimide, (ii) crystallisation, and (iii) controlled precipitation.

Description

Process for preparing (11 β, 16a)-9-fluoro-11 -hydroxy-16,17-[1 -methyl- ethylidenebis(oxy)]-21 -[1 -oxo-[4-(nitrooxymethyl)benzoxy]]pregna-1 ,4- dien-3,20-dione Field of the invention
This invention relates to a new process for the preparation of the compound (1 1 β, 16a)-9-fluoro-1 1 -hydroxy-16,17-[1 -methyl- ethyl idenebis(oxy)]-21 -[1 -oxo-[4-(nitrooxymethyl)benzoxy]]pregna-1 ,4-dien- 3,20-dione, used as a topic anti-inflammatory drug.
Background art
Compound (1 1 β, 16a)-9-fluoro-1 1 -hydroxy-16,17-[1 -methyl- ethylidenebis(oxy)]-21 -[1 -oxo-[4-(nitrooxymethyl)benzoxy]]pregna-1 ,4-dien- 3,20-dione with formula (I) is a corticosteroid previously described in application WO2007025632 (Example 1 ). This compound is especially useful in the treatment of certain inflammatory diseases such as corticosteroid- sensitive dermatosis, atopic dermatitis, contact dermatitis, psoriasis and seborrhoeic dermatitis.
Said compound is applied topically, preferably using creams, ointments, lotions and gels and similar formulations. The compound of formula (I) is obtained in example 1 of application WO2007025632 by the reaction of triamcinolone acetonide (II) with 4- (nitrooxymethyl)benzoic acid (III) in the presence of 1 -ethyl-3-(3- dimethylaminopropyl)carbodiimide (IV) and 4-dimethylaminopyridine (V) according to Diagram 1 .
Diagram 1
The yield of this reaction is of 34.4%, which makes it industrially unviable. Also, the price of the diimide used (IV) is also a drawback for use in industrial processes.
It is therefore necessary to find a different process for the industrial production of compound (I) with a high yield and using cheaper starting products. The authors of the present invention have achieved a new industrial process to obtain (I) that produces the product with a much higher yield and also replaces diimide (IV) with Ν,Ν'-diisopropylcarbodiimide (VI), which is cheaper. On the other hand, we have found that the resulting product is of very high purity. Moreover, the new process also comprises a final step of controlled precipitation, which provides the end product with a suitable particle size for the preparation of topical formulations. Summary of the invention
In a single aspect, the invention provides a new industrial process for preparing (1 1 β, 16a)-9-fluoro-1 1 -hydroxy-16,17-[1 -methyl-ethyl idenebis(oxy)]- 21 -[1 -oxo-[4-(nitrooxymethyl)benzoxy]]pregna-1 ,4-dien-3,20-dione (I) with a good yield, starting from cost effective products and providing an end product with suitable purity and particle size.
Detailed description of the invention The process for preparing 1 1 β, 16a)-9-fluoro-1 1 -hydroxy-16,17-[1 - methyl-ethylidenebis(oxy)]-21 -[1 -oxo-[4-(nitrooxymethyl)benzoxy]]pregna-1 ,4- dien-3,20-dione (I), which is the single aspect of the invention, comprises the following steps:
(i) reaction of triamcinolone acetonide (II)
with 4-(nitrooxymethyl)benzoic acid (III), 4-dimethylaminopyridine (V) and N,N'-diisopropylcarbodiimide (VI)
in an inert solvent, followed by the elimination by filtration or centrifuging of the solid formed, which consists mainly of Ν,Ν'- diisopropylurea, acidification of the liquid phase, neutralising and washout thereof with water, adding an inert anti-solvent to the organic phase and separating the compound (I) thus formed by filtration or centrifuging; (ii) crystallisation of compound (I) formed in step (i) in a mixture of a solvent and an anti-solvent; and
(iii) precipitation of the compound (I) crystallised in step (ii) in a mixture of a solvent and an anti-solvent. In a preferred embodiment, the solvent of step (i) is chosen from the group consisting of halogenated hydrocarbons such as dichloromethane, amides such as dimethylformamide and dimethylacetamide, cyclic ethers such as tetrahydrofurane, ketones such as acetone and methyl isobutyl ketone, esters such as ethyl acetate and isopropyl acetate, nitriles such as acetonitrile, sulphoxides such as dimethyl sulphoxide and similar solvents and mixtures thereof. The solvent is preferably dichloromethane.
In another preferred embodiment, the acidification is performed with an acid chosen from the group consisting of mineral acids such as hydrochloric acid, sulphuric acid, phosphoric acid and hydrobromic acid, carboxylic acids such as acetic acid, trifluoroacetic acid and formic acid, sulphonic acids such as methane sulphonic acid, trifluoromethane sulphonic acid and p-toluene sulphonic acid and other similar acids and mixtures thereof. The acid is preferably hydrochloric acid.
In another preferred embodiment, the neutralisation is performed with a base chosen from the group consisting of alkaline bicarbonates such as sodium bicarbonate and potassium bicarbonate and alkaline carbonate such as sodium carbonate and potassium carbonate. The base is preferably sodium bicarbonate.
In another embodiment preferred, the anti-solvent of step (i) is chosen from the group consisting of Ci-C4 alkanols such as ethanol, methanol and isopropanol, aromatic hydrocarbons such as toluene and xylenes, as well as water and other similar anti-solvents and mixtures thereof. The anti-solvent is preferably ethanol.
In another preferred embodiment, the solvent of step (ii) is chosen from the group consisting of halogenated hydrocarbons such as dichloromethane, amides such as dimethylformamide and dimethylacetamide, cyclic ethers such as tetrahydrofurane, ketones such as acetone and methyl isobutyl ketone, esters such as ethyl acetate and isopropyl acetate, nitriles such as acetonitrile, sulphoxides such as dimethyl sulphoxide and similar solvents and mixtures thereof. The solvent is preferably dichloromethane. In another preferred embodiment, the anti-solvent of step (ii) is chosen from the group consisting of Ci-C4 alkanols such as ethanol, methanol and isopropanol, aromatic hydrocarbons such as toluene and xylenes, as well as water and other similar anti-solvents and mixtures thereof. The anti-solvent is preferably ethanol.
In another preferred embodiment, the solvent of step (iii) is chosen from the group consisting of esters such as ethyl acetate and isopropyl acetate, amides such as dimethylformamide and dimethylacetamide, cyclic ethers such as tetrahydrofurane, ketones such as acetone and methyl isobutyl ketone, nitriles such as acetonitrile, halogenated hydrocarbons such as dichloromethane and sulphoxides such as dimethyl sulphoxide and similar solvents and mixtures thereof. The solvent is preferably ethyl acetate.
In another preferred embodiment, the anti-solvent of step (iii) is chosen from a group consisting of C6-C9 aliphatic hydrocarbons such as heptane, aliphatic ethers such as isopropyl ether and ethyl ether, the group consisting of Ci-C4 alkanols such as ethanol, methanol and isopropanol, and similar anti- solvents and mixtures thereof. The anti-solvent is preferably heptane. Examples Example 1
Synthesis of (1 13, 16a)-9-fluoro-1 1 -hvdroxy-16.17-ri-methyl- ethyl idenebis(oxy)1-21 -[1 -oxo-[4-(nitrooxymethyl)benzoxy1lpregna-1 ,4-dien-
3,20-dione (I)
Diagram 2
(i) Reaction
12.92 Kg of triamcinolone acetonide (II), 6.50 Kg of 4-(nitrooxymethyl)benzoic acid (III), 401 g of 4-dimethylaminopyridine (V) and 5.8 I of Ν,Ν'- diisopropylcarbodiimide (VI) were added to 284 I of dichloromethane. The solution was placed at ambient temperature and maintained with stirring until the reaction was completed. 13 I of dichloromethane were added. The solid formed (Ν,Ν'-diisopropylurea) was removed by filtration and the filter was washed with dichloromethane.
The dichloromethane extracts were placed together and 203 I of 0.5 N HCI were added. 203 I of 0.5 N HCI were added to the organic phase, followed by 129 I of 0.25 N NaHCO3. It was washed with water until the pH of the aqueous phase was similar to that of the water added.
465 I of absolute ethanol were added to the organic phase and it was distilled at atmospheric pressure to a final volume of between 465 I and 504 I, and it was left to reach room temperature.
The suspension was filtered and the wet solid was washed with ethanol. The wet solid was dried under vacuum, producing 15.59 Kg of compound (I). Yield = 85.5%. HPLC Purity = 98.41 %.
(ii) Crystallisation 15.56 Kg of the solid obtained in the previous step were added to 467 I of dichloromethane. This was heated to reflux and distilled at atmospheric pressure to a final volume of 47 I. It was left to reach ambient temperature and 560 I of ethanol were added. The suspension was filtered and the wet solid was washed with ethanol.
The wet solid was dried under vacuum.
(iii) Precipitation
1 1 .21 Kg of the solid obtained in the previous step were added to 516 I of ethyl acetate. It was heated to reflux and stirred until solution. It was cooled to 40-50°C. 538 I of heptane were added and it was taken to ambient temperature. The solution was filtered through a 0.2 μιτι filter. It was washed with ethyl acetate and stirred at least for 3 hours at ambient temperature.
The suspension was filtered and the wet solid was washed with heptane. The wet solid was dried under vacuum. Example 2
Particle size distribution for (I)
The particle size distribution of the product obtained in the final step of Example 1 showed a Gaussian distribution characterised by values d(0.9) = 10.79 pm; d(0.5) = 5.26 pm; and d(0.1 ) = 2.34 μητι.

Claims

1 . A process for preparing (1 1 β, 16a)-9-fluoro-1 1 -hydroxy-16,17-[1 -methyl- ethyl idenebis(oxy)]-21 -[1 -oxo-[4-(nitrooxymethyl)benzoxy]]pregna-1 ,4-dien- 3,20-dione (I)
comprising the following steps:
(i) reaction of triamcinolone acetonide (II)
with 4-(nitrooxymethyl)benzoic acid (III), 4-dimethylaminopyridine (V) and Ν,Ν'-diisopropylcarbodiimide (VI) in an inert solvent, elimination by filtration or centrifuging of the solid formed, acidification of the liquid phase, neutralising and washout thereof with water, adding an inert anti-solvent to the organic phase and separating the compound (I) thus formed by filtration or centrifuging;
(ii) crystallisation of compound (I) formed in step (i) in a mixture of a solvent and an anti-solvent; and
(iii) precipitation of the compound (I) crystallised in step (ii) in a mixture of a solvent and an anti-solvent.
2. The process according to claim 1 , wherein the solvent of step (i) is chosen from the group consisting of dichloromethane, dimethylformamide, tetrahydrofurane, acetone, acetonitrile, ethyl acetate, isopropyl acetate, methyl isobutyl ketone, dimethylacetamide and dimethyl sulphoxide.
3. The process according to claim 2, wherein the solvent is dichloromethane.
4. The process according to claim 1 , wherein the acidification is performed with an acid chosen from the group consisting of hydrochloric acid, sulphuric acid, acetic acid, trifluoroacetic acid, hydrobromic acid, formic acid, methane sulphonic acid, trifluoromethane sulphonic acid and p- toluene sulphonic acid.
5. The process according to claim 4, wherein the acid is hidrochloric acid.
6. The process according to claim 1 , wherein the neutralising is performed with a base chosen from the group consisting of sodium bicarbonate, potassium bicarbonate, sodium carbonate and potassium carbonate.
7. The process according to claim 6, wherein the base is sodium bicarbonate.
8. The process according to claim 1 , wherein the anti-solvent of step (i) is chosen from the group consisting of ethanol, methanol, isopropanol, toluene and water.
9. The process according to claim 8, wherein the anti-solvent is ethanol.
10. The process according to claim 1 , wherein the solvent of step (ii) is chosen from the group consisting of dichloromethane, dimethylformamide, tetrahydrofurane, acetone, acetonitrile, ethyl acetate, isopropyl acetate, methyl isobutyl ketone, dimethylacetamide and dimethyl sulphoxide.
1 1 . The process according to claim 10, wherein the solvent is dichloromethane.
12. The process according to claim 1 , wherein the anti-solvent of step (ii) is chosen from the group consisting of ethanol, methanol, isopropanol, toluene and water.
13. The process according to claim 12, wherein the anti-solvent is ethanol.
14. The process according to claim 1 , wherein the solvent of step (iii) is chosen from the group consisting of ethyl acetate, dimethylformamide, tetrahydrofurane, acetone, acetonitrile, dichloromethane, isopropyl acetate, methyl isobutyl ketone, dimethylacetamide and dimethyl sulphoxide.
15. The process according to claim 14, wherein the solvent is ethyl acetate.
16. The process according to claim 1 , wherein the anti-solvent of step (iii) is chosen from the group consisting of heptane, isopropyl ether and isopropanol.
17. The process according to claim 16, wherein the anti-solvent is heptane.
EP10776364A 2009-11-16 2010-11-15 Process for preparing (11beta, 16alpha)-9-fluoro-11-hydroxy-16,17-[1-methyl-ethylidenebis(oxy)]-21-[1-oxo-[4-(nitrooxymethyl)benzoxy]]pregna-1,4-dien-3,20-dione Withdrawn EP2501710A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200930999A ES2359708B1 (en) 2009-11-16 2009-11-16 PREPARATION PROCEDURE OF THE (11BETA, 16ALFA) -9-FLUORO-11-HIDROXI-16,17- [1-METHYL-ETHYLENEBIS (OXI)] - 21- [1-OXO- [4- (NITROOXIMETILE) BENZOXI]] PREÑA-1,4-DIEN-3,20-DIONA.
PCT/EP2010/067443 WO2011058161A2 (en) 2009-11-16 2010-11-15 Process for preparing (11beta, 16alpha)-9-fluoro-11-hydroxy-16,17-[1-methyl-ethylidenebis(oxy)]-21-[1-oxo-[4-(nitrooxymethyl)benzoxy]]pregna-1,4-dien-3,20-dione

Publications (1)

Publication Number Publication Date
EP2501710A2 true EP2501710A2 (en) 2012-09-26

Family

ID=43896867

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10776364A Withdrawn EP2501710A2 (en) 2009-11-16 2010-11-15 Process for preparing (11beta, 16alpha)-9-fluoro-11-hydroxy-16,17-[1-methyl-ethylidenebis(oxy)]-21-[1-oxo-[4-(nitrooxymethyl)benzoxy]]pregna-1,4-dien-3,20-dione

Country Status (16)

Country Link
EP (1) EP2501710A2 (en)
JP (1) JP2013510826A (en)
KR (1) KR20120084788A (en)
CN (1) CN102612522A (en)
AR (1) AR078909A1 (en)
AU (1) AU2010317895A1 (en)
BR (1) BR112012011552A2 (en)
CA (1) CA2780139A1 (en)
ES (1) ES2359708B1 (en)
MX (1) MX2012005616A (en)
PE (1) PE20121315A1 (en)
PH (1) PH12012500923A1 (en)
RU (1) RU2012124815A (en)
TW (1) TW201130861A (en)
UY (1) UY33032A (en)
WO (1) WO2011058161A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106632562B (en) * 2015-10-30 2020-02-18 天津法莫西医药科技有限公司 Fluorometholone refining process

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1238912B (en) * 1964-01-31 1967-04-20 Thomae Gmbh Dr K Process for the preparation of new esters of triamcinolone-16alpha, 17alpha-acetonide
US4323512A (en) * 1981-05-13 1982-04-06 Schering Corporation Process for the preparation of steroidal 17α-arylcarboxylates
GB9919693D0 (en) * 1999-08-19 1999-10-20 Rhone Poulenc Rorer Ltd Process
US6696592B2 (en) * 2001-05-22 2004-02-24 Nicox-S.A. Methods of making 21-[4′-(nitrooxyalkyl)benzoate] corticosteroid derivatives and intermediates useful in the synthesis thereof
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
CN102134269A (en) * 2005-09-02 2011-07-27 尼科克斯公司 Nitrooxy derivatives of glucocorticoids
EP1964550A1 (en) * 2007-03-01 2008-09-03 NicOx S.A. Glucocorticoid-nitrooxyderivative compositions
ES2324007A1 (en) * 2007-10-25 2009-07-28 Ferrer Internacional, S.A. Amorphous form of (11beta,16alpha)-9-fluoro-11-hydroxy-16,17-[(1-methylethyliden)bis(oxy)]-21-[[4- [(nitrooxy)methyl]benzoyl]oxy]-pregna-1,4-dien-3,20-dione

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011058161A2 *

Also Published As

Publication number Publication date
WO2011058161A2 (en) 2011-05-19
WO2011058161A3 (en) 2011-07-07
AR078909A1 (en) 2011-12-14
MX2012005616A (en) 2012-10-15
CN102612522A (en) 2012-07-25
PH12012500923A1 (en) 2017-08-23
RU2012124815A (en) 2013-12-27
JP2013510826A (en) 2013-03-28
PE20121315A1 (en) 2012-10-06
UY33032A (en) 2011-05-31
BR112012011552A2 (en) 2015-10-06
ES2359708A1 (en) 2011-05-26
ES2359708B1 (en) 2012-03-30
AU2010317895A1 (en) 2012-05-24
TW201130861A (en) 2011-09-16
KR20120084788A (en) 2012-07-30
CA2780139A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
AU2007298770B2 (en) Processes for the preparation of ciclesonide and its crystal form
WO2012110947A1 (en) An improved process for preparation of levonorgestrel
WO2017208165A1 (en) Process for preparation of obeticholic acid
JP2015509493A (en) New method for producing ciclesonide
JP4456811B2 (en) Process for producing 16,17-[(cyclohexylmethylene) bis (oxy)]-11,12-dihydroxy-pregna-1,4-diene-3,20-dione or its 21-isobutyrate by ketal exchange reaction
UA60333C2 (en) A PROCESS FOR PRODUCING Mometasone furoate
WO2011058161A2 (en) Process for preparing (11beta, 16alpha)-9-fluoro-11-hydroxy-16,17-[1-methyl-ethylidenebis(oxy)]-21-[1-oxo-[4-(nitrooxymethyl)benzoxy]]pregna-1,4-dien-3,20-dione
WO2009112557A2 (en) Process for the preparation of pregnane derivatives
WO2008087667A1 (en) Preparative process for artesunate from artemisinin
US20070117974A1 (en) One-pot processes for preparing prednisolone derivatives
EP2938625B1 (en) Process for the preparation of abiraterone acetate
CN104945357A (en) Refining method of dehydroandrographolide succinate
CA2584052C (en) Process for the esterification of a carbothioic acid
KR101088892B1 (en) Method for preparing 4-cyano benzyl bromide
US9145439B2 (en) Process for the preparation of 6-alpha-fluoro pregnanes
CA2780566A1 (en) Process for preparing 4-nitro-oxy-methyl-benzoic acid
ITMI20081429A1 (en) PROCESS FOR THE STEREOSELECTIVE SYNTHESIS OF THE 22-R EPIMERO DI CICLESONIDE
KR20100122592A (en) Orlistat crystalline form and process for preparing the same
US20110009654A1 (en) 11b-fluoro-3-acetoxyestra-3,5-dien-17-one and method for the production thereof
CN104478766A (en) Method for preparing high-purity acetyl homotaurine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120607

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SOBRAL, LUIS

Inventor name: ALVAREZ, CARLOS

Inventor name: PALOMER, ALBERT

Inventor name: ANGLADA, LUIS

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NICOX S.A.

Owner name: FERRER INTERNACIONAL, S.A.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140603